Premium
Comparative anticholinergic activity of oxaprotiline and amitriptyline
Author(s) -
Roffman Mark,
Gould Eugene,
Brewer Samuel,
Lau Helen,
Sachais Barry,
Dixon Nina,
Kaczmarek Linda,
Le Sher Anne
Publication year - 1983
Publication title -
drug development research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.582
H-Index - 60
eISSN - 1098-2299
pISSN - 0272-4391
DOI - 10.1002/ddr.430030608
Subject(s) - anticholinergic , amitriptyline , dry mouth , placebo , anesthesia , blurred vision , sedation , antidepressant , depression (economics) , medicine , psychology , anxiety , psychiatry , saliva , alternative medicine , pathology , economics , macroeconomics
As part of a double‐blind multicenter trial comparing oxaprotiline with amitriptyline and placebo in 308 outpatients with moderate depression, objective (salivary flow) and subjective (dry mouth, blurred vision/visual disorder, and constipation) determinants of anticholinergic activity were assessed. Both active treatments, but not placebo, induced approximately a 40% reduction in salivary flow after one week of treatment with 75 mg/day h.s. Whereas amitriptyline caused a further reduction (26%) in salivary flow by the end of the trial (week 5), no such reduction was noted with oxaprotiline. With regards to subjective complaints, more patients experienced dry mouth and blurred vision/visual degree of sedation is related to the degree of anticholinergic effects per se. Rather, the sedation may be related to a specific anticholinergic effect, such as changes in salivary flow.